Evidence map›Paper›PMID 38515460›Full record

ArticlePeerJ2024

Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform.

Xiong Shu, Hui Wen Zhang, Shi Ya Liu, Li Xin Sun, Tao Zhang, Yu Liang Ran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Role of ENO1 and its targeted therapy in tumors.Journal of translational medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xiong ShuNational Center for Orthopaedics, Beijing Research Institute of Traumatology and Orthopaedics, Beijing JiShuiTan Hospital, Beijing, China.
Hui Wen ZhangState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shi Ya LiuState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Xin SunState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tao ZhangThe Second People's Hospital of Xining, Xining, China.
Yu Liang RanState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Jishuitan Hospital · CNXintai People's Hospital · CN

Funding

Beijing Municipal Health CommissionBeijing Natural Science FoundationCAMS Innovation Fund for Medical SciencesIndependent Issue of State Key Laboratory of Molecular OncologyNational Natural Science Foundation of ChinaQinghai Provincial Science and Technology Department Applied Basic Research Program
6 · The paper itself

Abstract

Background: Antibody-based platforms ( Methods: The cell migration, invasion, drug resistance, and self-renewal were assessed by the cell invasion and migration assay, wound healing assay, CCK-8 assay, colony formation assay, and sphere formation assay, respectively. The expression profiles of CSCs (ALDH Results: In the present study, western blot and flow cytometry verified that anti-ENO1 antibody target the CD44 Conclusions: The study preliminarily revealed anti-ENO1 antibody combined with metformin could overcome drug resistance against CSCs by inhibiting the Wnt//β-catenin pathway and might serve as a potential precursor platform for screening ADC. More importantly, it is reasonably believed that antibody-based drug combination therapy might function as an encouraging tool for oncotherapy.

Indexed as

Metforminbeta CateninCell Line, TumorCetuximabCisplatinPhosphatidylinositol 3-Kinasesbeta CateninCetuximabCisplatinMetforminPhosphatidylinositol 3-KinasesAntibody-based drug combination therapyCancer stem cellsDrug resistanceENO1Oncotherapy

Identifiers

PMID38515460
PMCPMC10956521
OpenAlexW4392918287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.